A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Study Number

4890826

Phase

I/II

Age Group

Adult

Principal Investigator

Hamza Hassan

Purpose

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

Check your eligibility for this trial

Check now

Full Title

A Phase I/II, Multicenter, Open-label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma

ClinicalTrials.Gov ID

NCT07336472

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.